Inventor · disambiguated record
Martin Pulé
Also filed as: PULE MARTIN · PULÉ MARTIN
71 granted patents·89 pending applications·189 citations·filing 2013–2025
98Inventor score
Top patents by PatentIndex Score
160 records- 0196US11034750B2Chimeric antigen receptor (CAR) comprising a CD19-binding domainAUTOLUS LTD·Filed 2018·Granted Jun 15, 2021·8 cites·7 claims
- 0296US10172885B2CellUCL BUSINESS PLC·Filed 2014·Granted Jan 8, 2019·24 cites·17 claims
- 0395US12187769B2CellAUTOLUS LTD·Filed 2023·Granted Jan 7, 2025·2 cites·5 claims
- 0495US11091532B2T cell which co-expresses a CD19 chimeric antigen receptor and a CD22 chimeric antigen receptorAUTOLUS LTD·Filed 2015·Granted Aug 17, 2021·8 cites·16 claims
- 0594US11590170B2Chimeric antigen receptorAUTOLUS LTD·Filed 2022·Granted Feb 28, 2023·3 cites·6 claims
- 0693US10981970B2Chimeric antigen receptor (CAR) comprising a CD22-binding domainAUTOLUS LTD·Filed 2018·Granted Apr 20, 2021·4 cites·8 claims
- 0793US10800854B2Chimeric cytokine receptors and encoding nucleic acidsAUTOLUS LTD·Filed 2016·Granted Oct 13, 2020·6 cites·22 claims
- 0893US10172886B2CellUCL BUSINESS PLC·Filed 2014·Granted Jan 8, 2019·16 cites·16 claims
- 0993US10098926B2CellUCL BUSINESS PLC·Filed 2017·Granted Oct 16, 2018·10 cites·4 claims
- 1092US10800855B2Chimeric cytokine receptors and encoding nucleic acidsAUTOLUS LTD·Filed 2018·Granted Oct 13, 2020·4 cites·15 claims
- 1192US10730942B2Protein-based T-cell receptor knockdownUCL BUSINESS LTD·Filed 2017·Granted Aug 4, 2020·15 cites·4 claims
- 1291US10457730B2Chimeric antigen receptor (CAR) comprising a CD19-binding domainUCL BUSINESS PLC·Filed 2016·Granted Oct 29, 2019·19 cites·24 claims
- 1390US11058722B2Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domainAUTOLUS LTD·Filed 2016·Granted Jul 13, 2021·4 cites·13 claims
- 1490US10954530B2Retroviral and lentiviral vectorsAUTOLUS LTD·Filed 2016·Granted Mar 23, 2021·5 cites·12 claims
- 1590US10174099B2CellUCL BUSINESS PLC·Filed 2017·Granted Jan 8, 2019·5 cites·3 claims
- 1689US11851672B2CAR T-cells comprising transcriptional circuitsAUTOLUS LTD·Filed 2018·Granted Dec 26, 2023·3 cites·2 claims
- 1789US11365262B2CellAUTOLUS LTD·Filed 2016·Granted Jun 21, 2022·4 cites·19 claims
- 1889US2025353893A1CellAUTOLUS LTD·Filed 2025·Application pending·0 cites
- 1987US12049510B2Chimeric antigen receptorAUTOLUS LTD·Filed 2019·Granted Jul 30, 2024·2 cites·14 claims
- 2087US11180553B2Chimeric antigen receptorAUTOLUS LTD·Filed 2017·Granted Nov 23, 2021·4 cites·12 claims
- 2187US10654927B2Signalling systemUCL BUSINESS PLC·Filed 2015·Granted May 19, 2020·4 cites·16 claims
- 2286US12398194B2Cell lexpressing two chimeric antigen receptors (CARs) at the cell surfaceAUTOLUS LTD·Filed 2023·Granted Aug 26, 2025·0 cites·20 claims
- 2386US11479613B2Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteinsAUTOLUS LTD·Filed 2020·Granted Oct 25, 2022·1 cites·11 claims
- 2486US2024033292A1CellAUTOLUS LTD·Filed 2023·Application pending·0 cites
- 2585US11103532B2Chimeric proteinAUTOLUS LTD·Filed 2019·Granted Aug 31, 2021·2 cites·21 claims
- 2684US10160794B2Chimeric antigen receptorUCL BUSINESS PLC·Filed 2014·Granted Dec 25, 2018·7 cites·8 claims
- 2784US2024033289A1CellAUTOLUS LTD·Filed 2023·Application pending·0 cites
- 2883US12234295B2Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereofAUTOLUS LTD·Filed 2022·Granted Feb 25, 2025·0 cites·22 claims
- 2983US11701386B2CellAUTOLUS LTD·Filed 2018·Granted Jul 18, 2023·1 cites·7 claims
- 3083US10098911B2Chimeric proteinUCL BUSINESS PLC·Filed 2016·Granted Oct 16, 2018·5 cites·12 claims
- 3183US2025270279A1Polypeptide useful in adoptive cell therapyUCL BUSINESS LTD·Filed 2024·Application pending·0 cites
- 3282US11959084B2Nucleic acid constructAUTOLUS LTD·Filed 2019·Granted Apr 16, 2024·1 cites·21 claims
- 3382US10925943B2Marker-suicide gene useful in adoptive cell therapyUCL BUSINESS LTD·Filed 2013·Granted Feb 23, 2021·3 cites·12 claims
- 3482US2025368715A1Chimeric Antigen ReceptorAUTOLUS LTD·Filed 2025·Application pending·0 cites
- 3581US11982673B2MethodsAUTOLUS LTD·Filed 2022·Granted May 14, 2024·0 cites·10 claims
- 3681US11982672B2MethodsAUTOLUS LTD·Filed 2022·Granted May 14, 2024·0 cites·8 claims
- 3781US11885806B2Method for depleting malignant T-cellsAUTOLUS LTD·Filed 2022·Granted Jan 30, 2024·0 cites·10 claims
- 3881US11885807B2Method for depleting malignant T-cellsAUTOLUS LTD·Filed 2022·Granted Jan 30, 2024·0 cites·8 claims
- 3981US2025388929A1Retroviral and Lentiviral VectorsAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 4081US2023194535A1MethodsAUTOLUS LTD·Filed 2022·Application pending·0 cites
- 4181US2025197464A1CellAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 4280US11578126B2Chimeric antigen receptor (CAR) comprising a CD19-binding domainAUTOLUS LTD·Filed 2019·Granted Feb 14, 2023·1 cites·21 claims
- 4380US10919951B2Chimeric antigen receptorAUTOLUS LTD·Filed 2018·Granted Feb 16, 2021·2 cites·7 claims
- 4480US2025277047A1Chimeric antigen receptorAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 4579US11466070B2Signalling systemAUTOLUS LTD·Filed 2017·Granted Oct 11, 2022·2 cites·12 claims
- 4679US2024301088A1Chimeric antigen receptorAUTOLUS LTD·Filed 2023·Application pending·0 cites
- 4778US12454578B2Cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptorsAUTOLUS LTD·Filed 2022·Granted Oct 28, 2025·0 cites·4 claims
- 4878US11385233B2Methods of depleting malignant T-cellsAUTOLUS LTD·Filed 2018·Granted Jul 12, 2022·1 cites·9 claims
- 4978US11345734B2Chimeric T cellAUTOLUS LTD·Filed 2016·Granted May 31, 2022·1 cites·5 claims
- 5078US11242377B2Chimeric receptor with ligand binding exodomain and cytokine and T cell signalling endodomainsAUTOLUS LTD·Filed 2016·Granted Feb 8, 2022·1 cites·35 claims
Showing the top 50 of 160 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Martin Pulé files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →